Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01
Pharma Bio — listed sponsor · 2013 · Registration No. 77, 4 February 2013; protocol ИБХ-ТД01
Study data at a glance
- Participants or experimental model
- 142 planned participants; 14 listed sites; 12-week primary assessment
- Reported results
- Registry reproduction describes a Phase IV randomized, multicenter, double-blind, placebo-controlled add-on trial with ACR20 as the primary assessment. Listed dates: 4 February 2013 to 30 September 2016.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- ClinLine reproduces a registry record; the original regulatory entry was not independently recovered.
- Planned enrollment is not confirmed enrollment or completion. No results or primary-endpoint success were verified.
- Historical listed dates do not establish current trial status.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Third-party registry reproduction checked; protocol evidence only.
Recorded source-check date: 2026-11-05. This date does not imply a completed systematic review.
Source type: Third-party trial-registry reproduction
Citation and original source
Original source: Pharma Bio — listed sponsor. Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01 Registration No. 77, 4 February 2013; protocol ИБХ-ТД01 2013.
Molekul research summary: https://molekul.io/research/auto-thymodepressin-ra-protocol-2013. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry